MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Accelerate Diagnostics Interest Expense 2011-2026 | AXDX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Accelerate Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 235 K | -6.1 M | -14.5 M | 14.3 M | -7.75 M | 649 K | 394 K | -4 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.3 M | -14.5 M | -1.6 M |
Quarterly Interest Expense Accelerate Diagnostics
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 K | 13 K | - | -29 K | 40 K | 45 K | - | -49 K | -107 K | -50 K | - | -5 K | 4.18 M | 4.09 M | - | 3.96 M | 3.84 M | 3.75 M | - | 3.6 M | 3.53 M | 3.46 M | - | 3.36 M | 3.2 M | 158 K | - | - | - | - | - | - | - | - | - | -1 K | -2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.18 M | -107 K | 1.68 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 114.84 | -0.55 % | $ 34.9 B |  USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.3 | 0.62 % | $ 175 M |  China |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
8.26 M | $ 15.36 | 1.92 % | $ 1.99 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.2 | 0.33 % | $ 20 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.82 | -2.68 % | $ 950 M | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.59 | 1.57 % | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.15 | -4.17 % | $ 6.26 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 168.22 | -3.26 % | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.73 | -0.44 % | $ 687 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 114.22 | 1.41 % | $ 5.34 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 192.12 | 0.53 % | $ 137 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
177 M | $ 63.21 | 1.59 % | $ 24.7 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 198.96 | 0.91 % | $ 22.1 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 89.66 | -4.44 % | $ 11.2 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 109.62 | -4.0 % | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 1.97 | 0.63 % | $ 8.72 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 127.74 | 0.28 % | $ 20.3 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 170.72 | -1.47 % | $ 29.3 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 274.46 | 0.27 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 75.89 | -0.28 % | $ 5.12 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 496.0 | -0.47 % | $ 14.3 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 266.63 | 0.53 % | $ 26.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.67 | -1.68 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.02 | 0.25 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.56 | 1.59 % | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.33 | 0.99 % | $ 388 M | USA |